MovDisordV3, Main, Exploration, bibRecordById, Pascal:03-0040684

Progressive supranuclear palsy diagnosis and confounding features: Report on 16 autopsied cases

Identifieur interne : 004321 ( Main/Exploration ); précédent : 004320; suivant : 004322

Progressive supranuclear palsy diagnosis and confounding features: Report on 16 autopsied cases

Auteurs : Sam Birdi [Canada] ; Ali H. Rajput [Canada] ; Mark Fenton [Canada] ; Jeffery R. Donat [Canada] ; Bohdan Rozdilsky [Canada] ; Christopher Robinson [Canada] ; Rob Macaulay [Canada] ; David George [Canada]

Source :

Movement Disorders [ 0885-3185 ] ; 2002-11.

RBID : ISTEX:D1EE5808C9DB03F2371033F27730FFC47B3F2AD2

Descripteurs français

Pascal (Inist)
- Autopsie, Diagnostic, Homme, Lévodopa, Ophtalmoplégie supranucléaire, Progressif, Symptomatologie.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Aged, Aged, 80 and over, Autopsy, Brain (pathology), Diagnosis, Diagnosis, Differential, Dopamine Agonists (therapeutic use), Drug Therapy, Combination, Female, Human, Humans, Levodopa, Levodopa (therapeutic use), Magnetic Resonance Imaging, Male, Middle Aged, Neurologic Examination (drug effects), Prognosis, Progressive, Supranuclear Palsy, Progressive (diagnosis), Supranuclear Palsy, Progressive (drug therapy), Supranuclear Palsy, Progressive (pathology), Supranuclear ophthalmoplegia, Symptomatology, Treatment Outcome, diagnosis, levodopa treatment, prognosis, progressive supranuclear palsy.
MESH :
- chemical , therapeutic use : Dopamine Agonists, Levodopa.
- diagnosis : Supranuclear Palsy, Progressive.
- drug effects : Neurologic Examination.
- drug therapy : Supranuclear Palsy, Progressive.
- pathology : Brain, Supranuclear Palsy, Progressive.
- Aged, Aged, 80 and over, Diagnosis, Differential, Drug Therapy, Combination, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Prognosis, Treatment Outcome.

Abstract

We evaluated 16 (15 men, 1 woman) autopsy‐verified progressive supranuclear palsy (PSP) cases during 31 years (1969–2000) for clinical diagnosis and the course of the disease. The onset was gait difficulty or postural instability in 9 (56.3%), general motor slowing in 3 (18.8%), and tremor in 2. One case had onset with cognitive decline and 1 as hemidystonia. Four cases had supranuclear ophthalmoplegia (SNO) at the first assessment and were diagnosed as PSP. By last assessment, PSP diagnosis was made in 4 additional cases, but in 8 (50%) who never manifested ophthalmoplegia (mean 9.8 years after onset), PSP diagnosis was not made. Other manifestations included bulbar symptoms in 13 (81.3%), and cognitive impairment in 10 (62.5%) during the course of illness. Fifteen cases received levodopa, amantadine, anticholinergics, dopamine agonists, and selegiline in different combinations with symptomatic benefit in 9 of 15 (60%). Five had some improvement on levodopa alone and 3 showed more improvement when a dopamine agonist was added to levodopa. In general, the benefit was minimal and occurred only early in the course of illness. The mean age at onset was 63.7 (range, 53–85) years. Mean duration at PSP diagnosis was 4.8 (range, 2–11) years. Mean survival was 8.6 (range, 3–24) years and mean age at death was 72.3 (range, 60–89) years. When the different diagnostic criteria recommended in the literature were used, the accuracy of clinical diagnosis did not improve substantially. © 2002 Movement Disorder Society

Url:

https://api.istex.fr/document/D1EE5808C9DB03F2371033F27730FFC47B3F2AD2/fulltext/pdf

DOI: 10.1002/mds.10211

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Progressive supranuclear palsy diagnosis and confounding features: Report on 16 autopsied cases</title>
<author><name sortKey="Birdi, Sam" sort="Birdi, Sam" uniqKey="Birdi S" first="Sam" last="Birdi">Sam Birdi</name>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
</author>
<author><name sortKey="Fenton, Mark" sort="Fenton, Mark" uniqKey="Fenton M" first="Mark" last="Fenton">Mark Fenton</name>
</author>
<author><name sortKey="Donat, Jeffery R" sort="Donat, Jeffery R" uniqKey="Donat J" first="Jeffery R." last="Donat">Jeffery R. Donat</name>
</author>
<author><name sortKey="Rozdilsky, Bohdan" sort="Rozdilsky, Bohdan" uniqKey="Rozdilsky B" first="Bohdan" last="Rozdilsky">Bohdan Rozdilsky</name>
</author>
<author><name sortKey="Robinson, Christopher" sort="Robinson, Christopher" uniqKey="Robinson C" first="Christopher" last="Robinson">Christopher Robinson</name>
</author>
<author><name sortKey="Macaulay, Rob" sort="Macaulay, Rob" uniqKey="Macaulay R" first="Rob" last="Macaulay">Rob Macaulay</name>
</author>
<author><name sortKey="George, David" sort="George, David" uniqKey="George D" first="David" last="George">David George</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:D1EE5808C9DB03F2371033F27730FFC47B3F2AD2</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1002/mds.10211</idno>
<idno type="url">https://api.istex.fr/document/D1EE5808C9DB03F2371033F27730FFC47B3F2AD2/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000246</idno>
<idno type="wicri:Area/Istex/Curation">000246</idno>
<idno type="wicri:Area/Istex/Checkpoint">002C12</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Birdi S:progressive:supranuclear:palsy</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12465065</idno>
<idno type="wicri:Area/PubMed/Corpus">003914</idno>
<idno type="wicri:Area/PubMed/Curation">003914</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003964</idno>
<idno type="wicri:Area/Ncbi/Merge">000937</idno>
<idno type="wicri:Area/Ncbi/Curation">000937</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000937</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Birdi S:progressive:supranuclear:palsy</idno>
<idno type="wicri:Area/Main/Merge">006326</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:03-0040684</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002570</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000751</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002636</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Birdi S:progressive:supranuclear:palsy</idno>
<idno type="wicri:Area/Main/Merge">006675</idno>
<idno type="wicri:Area/Main/Curation">004321</idno>
<idno type="wicri:Area/Main/Exploration">004321</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Progressive supranuclear palsy diagnosis and confounding features: Report on 16 autopsied cases</title>
<author><name sortKey="Birdi, Sam" sort="Birdi, Sam" uniqKey="Birdi S" first="Sam" last="Birdi">Sam Birdi</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, University of Saskatchewan, Saskatoon, Saskatchewan</wicri:regionArea>
<wicri:noRegion>Saskatchewan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, University of Saskatchewan, Saskatoon, Saskatchewan</wicri:regionArea>
<wicri:noRegion>Saskatchewan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fenton, Mark" sort="Fenton, Mark" uniqKey="Fenton M" first="Mark" last="Fenton">Mark Fenton</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, University of Saskatchewan, Saskatoon, Saskatchewan</wicri:regionArea>
<wicri:noRegion>Saskatchewan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Donat, Jeffery R" sort="Donat, Jeffery R" uniqKey="Donat J" first="Jeffery R." last="Donat">Jeffery R. Donat</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, University of Saskatchewan, Saskatoon, Saskatchewan</wicri:regionArea>
<wicri:noRegion>Saskatchewan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rozdilsky, Bohdan" sort="Rozdilsky, Bohdan" uniqKey="Rozdilsky B" first="Bohdan" last="Rozdilsky">Bohdan Rozdilsky</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Pathology, University of Saskatchewan, Saskatoon, Saskatchewan</wicri:regionArea>
<wicri:noRegion>Saskatchewan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Robinson, Christopher" sort="Robinson, Christopher" uniqKey="Robinson C" first="Christopher" last="Robinson">Christopher Robinson</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Pathology, University of Saskatchewan, Saskatoon, Saskatchewan</wicri:regionArea>
<wicri:noRegion>Saskatchewan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Macaulay, Rob" sort="Macaulay, Rob" uniqKey="Macaulay R" first="Rob" last="Macaulay">Rob Macaulay</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Pathology, University of Dalhousie, Halifax, Nova Scotia</wicri:regionArea>
<wicri:noRegion>Nova Scotia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="George, David" sort="George, David" uniqKey="George D" first="David" last="George">David George</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Pathology, University of Calgary, Calgary, Alberta</wicri:regionArea>
<orgName type="university">Université de Calgary</orgName>
<placeName><settlement type="city">Calgary</settlement>
<region type="state">Alberta</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2002-11">2002-11</date>
<biblScope unit="vol">17</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="1255">1255</biblScope>
<biblScope unit="page" to="1264">1264</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">D1EE5808C9DB03F2371033F27730FFC47B3F2AD2</idno>
<idno type="DOI">10.1002/mds.10211</idno>
<idno type="ArticleID">MDS10211</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Autopsy</term>
<term>Brain (pathology)</term>
<term>Diagnosis</term>
<term>Diagnosis, Differential</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (therapeutic use)</term>
<term>Magnetic Resonance Imaging</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neurologic Examination (drug effects)</term>
<term>Prognosis</term>
<term>Progressive</term>
<term>Supranuclear Palsy, Progressive (diagnosis)</term>
<term>Supranuclear Palsy, Progressive (drug therapy)</term>
<term>Supranuclear Palsy, Progressive (pathology)</term>
<term>Supranuclear ophthalmoplegia</term>
<term>Symptomatology</term>
<term>Treatment Outcome</term>
<term>diagnosis</term>
<term>levodopa treatment</term>
<term>prognosis</term>
<term>progressive supranuclear palsy</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Supranuclear Palsy, Progressive</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Supranuclear Palsy, Progressive</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Brain</term>
<term>Supranuclear Palsy, Progressive</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Diagnosis, Differential</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Magnetic Resonance Imaging</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Prognosis</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Autopsie</term>
<term>Diagnostic</term>
<term>Homme</term>
<term>Lévodopa</term>
<term>Ophtalmoplégie supranucléaire</term>
<term>Progressif</term>
<term>Symptomatologie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We evaluated 16 (15 men, 1 woman) autopsy‐verified progressive supranuclear palsy (PSP) cases during 31 years (1969–2000) for clinical diagnosis and the course of the disease. The onset was gait difficulty or postural instability in 9 (56.3%), general motor slowing in 3 (18.8%), and tremor in 2. One case had onset with cognitive decline and 1 as hemidystonia. Four cases had supranuclear ophthalmoplegia (SNO) at the first assessment and were diagnosed as PSP. By last assessment, PSP diagnosis was made in 4 additional cases, but in 8 (50%) who never manifested ophthalmoplegia (mean 9.8 years after onset), PSP diagnosis was not made. Other manifestations included bulbar symptoms in 13 (81.3%), and cognitive impairment in 10 (62.5%) during the course of illness. Fifteen cases received levodopa, amantadine, anticholinergics, dopamine agonists, and selegiline in different combinations with symptomatic benefit in 9 of 15 (60%). Five had some improvement on levodopa alone and 3 showed more improvement when a dopamine agonist was added to levodopa. In general, the benefit was minimal and occurred only early in the course of illness. The mean age at onset was 63.7 (range, 53–85) years. Mean duration at PSP diagnosis was 4.8 (range, 2–11) years. Mean survival was 8.6 (range, 3–24) years and mean age at death was 72.3 (range, 60–89) years. When the different diagnostic criteria recommended in the literature were used, the accuracy of clinical diagnosis did not improve substantially. © 2002 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
<region><li>Alberta</li>
</region>
<settlement><li>Calgary</li>
</settlement>
<orgName><li>Université de Calgary</li>
</orgName>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Birdi, Sam" sort="Birdi, Sam" uniqKey="Birdi S" first="Sam" last="Birdi">Sam Birdi</name>
</noRegion>
<name sortKey="Donat, Jeffery R" sort="Donat, Jeffery R" uniqKey="Donat J" first="Jeffery R." last="Donat">Jeffery R. Donat</name>
<name sortKey="Fenton, Mark" sort="Fenton, Mark" uniqKey="Fenton M" first="Mark" last="Fenton">Mark Fenton</name>
<name sortKey="George, David" sort="George, David" uniqKey="George D" first="David" last="George">David George</name>
<name sortKey="Macaulay, Rob" sort="Macaulay, Rob" uniqKey="Macaulay R" first="Rob" last="Macaulay">Rob Macaulay</name>
<name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
<name sortKey="Robinson, Christopher" sort="Robinson, Christopher" uniqKey="Robinson C" first="Christopher" last="Robinson">Christopher Robinson</name>
<name sortKey="Rozdilsky, Bohdan" sort="Rozdilsky, Bohdan" uniqKey="Rozdilsky B" first="Bohdan" last="Rozdilsky">Bohdan Rozdilsky</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004321 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004321 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:D1EE5808C9DB03F2371033F27730FFC47B3F2AD2
   |texte=   Progressive supranuclear palsy diagnosis and confounding features: Report on 16 autopsied cases
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Progressive supranuclear palsy diagnosis and confounding features: Report on 16 autopsied cases

Progressive supranuclear palsy diagnosis and confounding features: Report on 16 autopsied cases

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.